New results uphold previous findings regarding the efficacy of cabozantinib, nivolumab, and ipilumumab arm for advanced renal ...

Certain AEs May Indicate Improved PFS With Enfortumab Vedotin for Urothelial Carcinoma ...

Certain AEs May Indicate Improved PFS With Enfortumab Vedotin for Urothelial Carcinoma ...

Certain AEs May Indicate Improved PFS With Enfortumab Vedotin for Urothelial Carcinoma ...

Increase in QOL and decrease in sexual function are among the benefits and risks, respectively, of adding SADT to EBRT for intermediate-risk prostate cancer.

Increase in QOL and decrease in sexual function are among the benefits and risks, respectively, of adding SADT to EBRT for intermediate-risk prostate cancer.

Findings also suggested that an up-front dose reduction of enfortumab vedotin may benefit older patients with urothelial carcinoma.

MyCareGorithm was met with high approval from patients, companions, and physicians, with all 3 groups reporting they’d ...

Dr Mohan discusses with Nurse Goff, Dr Mohan, and Dr Nadeem strategies for maintaining continuity of care and communication between community centers and academic institutions during bispecific ...

Dr Mohan discusses with Dr Nadeem, Dr Mann, and Nurse Distaso the key factors for referring patients from community centers to academic institutions for bispecific therapy and strategies for ...

177Lu-PSMA-617 With Enzalutamide for mCRPC Boosts OS, QOL ...

177Lu-PSMA-617 With Enzalutamide for mCRPC Boosts OS, QOL ...